Signaturefd LLC Has $604,000 Stake in IQVIA Holdings Inc. (NYSE:IQV)

Signaturefd LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,548 shares of the medical research company’s stock after acquiring an additional 121 shares during the period. Signaturefd LLC’s holdings in IQVIA were worth $604,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of IQV. Jennison Associates LLC lifted its stake in IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after acquiring an additional 9,578 shares in the last quarter. PGGM Investments grew its position in IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares in the last quarter. Fiduciary Alliance LLC acquired a new position in IQVIA in the 1st quarter valued at approximately $1,864,000. SG Americas Securities LLC lifted its position in IQVIA by 80.1% in the 1st quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock worth $11,579,000 after buying an additional 20,369 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of IQVIA during the 1st quarter valued at $3,365,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQV opened at $211.71 on Friday. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm has a market capitalization of $38.59 billion, a P/E ratio of 27.49, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The stock’s 50 day moving average price is $238.71 and its two-hundred day moving average price is $230.92. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on IQV shares. Morgan Stanley increased their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. cut their price target on IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a research note on Wednesday. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Royal Bank of Canada started coverage on shares of IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective on the stock. Finally, Barclays decreased their target price on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.